PRALATREXATE for Hepatosplenic t-cell lymphoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 12 adverse event reports in the FDA FAERS database where PRALATREXATE was used for Hepatosplenic t-cell lymphoma.
Most Reported Side Effects for PRALATREXATE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 107 | 23.0% | 37 | 12 |
| Stomatitis | 93 | 20.0% | 30 | 33 |
| Platelet count decreased | 56 | 12.0% | 15 | 21 |
| Disease progression | 46 | 9.9% | 21 | 11 |
| Neutrophil count decreased | 40 | 8.6% | 13 | 16 |
| Anaemia | 39 | 8.4% | 7 | 21 |
| Pyrexia | 38 | 8.2% | 4 | 20 |
| Mucosal inflammation | 37 | 7.9% | 8 | 18 |
| Drug ineffective | 32 | 6.9% | 9 | 8 |
| Off label use | 30 | 6.4% | 6 | 10 |
| Death | 26 | 5.6% | 26 | 8 |
| Febrile neutropenia | 26 | 5.6% | 7 | 16 |
| Neutropenia | 24 | 5.2% | 6 | 13 |
| Thrombocytopenia | 23 | 4.9% | 6 | 10 |
| Therapeutic response decreased | 22 | 4.7% | 3 | 5 |
Other Indications for PRALATREXATE
Peripheral t-cell lymphoma unspecified (157)
Product used for unknown indication (68)
Cutaneous t-cell lymphoma (36)
Angioimmunoblastic t-cell lymphoma (24)
T-cell lymphoma (21)
Mycosis fungoides (17)
Angioimmunoblastic t-cell lymphoma stage iii (14)
Anaplastic large-cell lymphoma (13)
Peripheral t-cell lymphoma unspecified stage iv (13)
Angioimmunoblastic t-cell lymphoma stage iv (12)
Other Drugs Used for Hepatosplenic t-cell lymphoma
CYCLOPHOSPHAMIDE (106)
DOXORUBICIN (103)
VINCRISTINE (90)
ETOPOSIDE (63)
DEXAMETHASONE (48)
PREDNISONE (42)
CYTARABINE (33)
IFOSFAMIDE (32)
CARBOPLATIN (27)
METHOTREXATE (24)